Alvotech announces changes to the leadership team

Reykjavik, iceland, sept. 05, 2023 (globe newswire) -- alvotech (nasdaq: alvo, the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that faysal kalmoua has been appointed alvotech's chief operating officer and hafrun fridriksdottir is stepping down following resubmission of the biologics license application (bla) for avt02, alvotech's proposed high-concentration interchangeable biosimilar to humira® (adalimumab).
ALVO Ratings Summary
ALVO Quant Ranking